RIEFLIN WILLIAM JL
SEC insider (Form 3/4/5 filer). CIK 0001182471. Director at Lycia Therapeutics, Inc. (LYCA) and 1 other issuer. 4 reported Form 4/5 transactions since Sep 2024; latest on Oct 22, 2026. Located in SOUTH SAN FRANCISCO, CA.
Companies RIEFLIN WILLIAM JL has filed insider reports for
- Lycia Therapeutics, Inc. (LYCA): Director
- Lyell Immunopharma, Inc. (LYEL): Director
RIEFLIN WILLIAM JL
CIK: 0001182471
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (4 total)
- Oct 22, 2026LYCA
Lycia Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
20K shares- - Aug 11, 2026LYCA
Lycia Therapeutics, Inc.
AwardDirectStock Option (Right to Buy)
24.8K shares- - Jun 10, 2026LYEL
Lyell Immunopharma, Inc.
AwardDirectOption (right to buy)
9.3K shares- - May 15, 2025LYEL
Lyell Immunopharma, Inc.
AwardDirectOption (right to buy)
130K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Oct 22, 2026 |  LYCA Lycia Therapeutics, Inc. | Award Stock Option (Right to Buy) | 20,000 | - | - | Direct |
| Aug 11, 2026 | LYCA Lycia Therapeutics, Inc. | Award Stock Option (Right to Buy) | 24,840 | - | - | Direct |
| Jun 10, 2026 |  LYEL Lyell Immunopharma, Inc. | Award Option (right to buy) | 9,250 | - | - | Direct |
| May 15, 2025 | LYEL Lyell Immunopharma, Inc. | Award Option (right to buy) | 130,000 | - | - | Direct |
1-4 of 4 transactions